Table 4.
Univariate and multivariate analysis of the overall survival of 15 patients with appendiceal GCCs and PC after CRS–HIPEC
| Characteristic | Univariate
|
Multivariate
|
||
|---|---|---|---|---|
| P-value | OR (95% CI) | P-value | OR (95% CI) | |
| Gender | 0.455 | 0.257–20.690 | ||
| Age (<50 vs ≥50) | 0.085 | 0.055–1.205 | ||
| Neoadjuvant chemotherapy | 0.342 | 0.421–12.082 | ||
| L-HIPEC | 0.214 | 0.031–2.188 | ||
| PCI (≥27 vs <27) | 0.049 | 1.006–37.835 | 0.416 | 0.019–5.120 |
| HIPEC (HIPEC vs no HIPEC) | 0.012 | 0.006–0.542 | 0.022 | 0.001–0.574 |
| HIPEC (mitomycin C vs 5FU/oxaliplatin) | 0.706 | 0.000–2668832 | ||
| Postop PCI (≥20 vs <20) | 0.053 | 0.969–87.269 | ||
| CC score (CC0 vs CC1–3) | 0.138 | 0.587–47.032 | ||
| Morbidity (grade 0–1 vs grade 2–5) | 0.917 | 0.221–5.348 | ||
| EPIC | 0.980 | 0.090–10.506 | ||
| Blood loss (≥1000 mL vs <1000 mL) | 0.152 | 0.562–41.396 | ||
| OP time | 0.589 | 0.143–3.014 | ||
| Cytology positive | 0.471 | 0.124–2.623 | ||
| Cell type (signet-ring vs papillary/tubular) | 0.976 | 0.197–5.340 | ||
| Positive LN metastasis | 0.690 | 0.174–14.066 | ||
| Adjuvant chemotherapy | 0.073 | 0.012–1.218 | ||
Note: Values shown in bold have significance of P-value <0.05.
Abbreviations: 5-FU, 5-fluorouracil; CC, completeness of cytoreduction; CRS, cytoreductive surgery; EPIC, early postoperative intraperitoneal chemotherapy; GCCs, goblet cell carcinomas; HIPEC, hyperthermic intraperitoneal chemotherapy; L-HIPEC, laparoscopic HIPEC; LN, lymph node; OP, operation; OR, odds ratio; PC, peritoneal carcinomatosis; PCI, peritoneal cancer index; Postop, postoperative.